person · Reporting owner

BREUIL ROBERT S

Disclosed activity across 2 companies

Tapewire entity: 115115
SEC CIK: 0001241009

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CalciMedica, Inc.GRAY · Entity 7804	Chief Financial Officer	March 23, 2023	March 27, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CalciMedica, Inc.

Report date March 23, 2023 · Filed March 27, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	35,326	Ending reported balance After 2023-03-23 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2023-03-23 · Disposition to issuer · Acquired 36,657 · Balance 48,003 F1: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Robert S. Breuil's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. Row 2 · 2023-03-23 · Tax withholding · Disposed 12,677 · Balance 35,326
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2023-03-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-03-23 · Disposition to issuer · Disposed 36,657 · Balance 0 F1: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Robert S. Breuil's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Robert S. Breuil's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Corium International, Inc.

Report date November 27, 2018 · Filed November 28, 2018

Section 16 reporting ended · disclosed 2018-11-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-11-27 transaction · row 1 1 source row Row 1 · 2018-11-27 · Disposition to issuer · Disposed 14,441 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR").
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.22 · Expires 2022-12-12	Direct	Reported balance After 2018-11-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-11-27 · Disposition to issuer · Disposed 167,529 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2024-01-26	Direct	Reported balance After 2018-11-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-11-27 · Disposition to issuer · Disposed 17,962 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2024-12-02	Direct	Reported balance After 2018-11-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-11-27 · Disposition to issuer · Disposed 27,883 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.22 · Expires 2022-12-12	Direct	Reported balance After 2018-11-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-11-27 · Disposition to issuer · Disposed 10,688 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2024-01-26	Direct	Reported balance After 2018-11-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-11-27 · Disposition to issuer · Disposed 23,621 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2024-12-02	Direct	Reported balance After 2018-11-27 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-11-27 · Disposition to issuer · Disposed 55,346 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.94 · Expires 2025-12-07	Direct	Reported balance After 2018-11-27 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-11-27 · Disposition to issuer · Disposed 36,458 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested option to purchase Shares that was unexpired, unexercised and outstanding was converted into and substituted for the right to receive an amount equal to the product of (x) the number of unvested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option. This consideration will be paid monthly in accordance with the monthly vesting schedule that originally was applicable to such option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.59 · Expires 2026-12-21	Direct	Reported balance After 2018-11-27 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2018-11-27 · Disposition to issuer · Disposed 32,344 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.59 · Expires 2027-11-30	Direct	Reported balance After 2018-11-27 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2018-11-27 · Disposition to issuer · Disposed 12,031 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.94 · Expires 2025-12-07	Direct	Reported balance After 2018-11-27 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2018-11-27 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested option to purchase Shares that was unexpired, unexercised and outstanding was converted into and substituted for the right to receive an amount equal to the product of (x) the number of unvested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option. This consideration will be paid monthly in accordance with the monthly vesting schedule that originally was applicable to such option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.59 · Expires 2026-12-21	Direct	Reported balance After 2018-11-27 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2018-11-27 · Disposition to issuer · Disposed 17,038 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested option to purchase Shares that was unexpired, unexercised and outstanding was converted into and substituted for the right to receive an amount equal to the product of (x) the number of unvested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option. This consideration will be paid monthly in accordance with the monthly vesting schedule that originally was applicable to such option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.59 · Expires 2027-11-30	Direct	Reported balance After 2018-11-27 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2018-11-27 · Disposition to issuer · Disposed 10,573 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested option to purchase Shares that was unexpired, unexercised and outstanding was converted into and substituted for the right to receive an amount equal to the product of (x) the number of unvested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option. This consideration will be paid monthly in accordance with the monthly vesting schedule that originally was applicable to such option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2024-12-02	Direct	Reported balance After 2018-11-27 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2018-11-27 · Disposition to issuer · Disposed 1,771 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested option to purchase Shares that was unexpired, unexercised and outstanding was converted into and substituted for the right to receive an amount equal to the product of (x) the number of unvested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option. This consideration will be paid monthly in accordance with the monthly vesting schedule that originally was applicable to such option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.94 · Expires 2025-12-07	Direct	Reported balance After 2018-11-27 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2018-11-27 · Disposition to issuer · Disposed 1,042 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested option to purchase Shares that was unexpired, unexercised and outstanding was converted into and substituted for the right to receive an amount equal to the product of (x) the number of unvested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option. This consideration will be paid monthly in accordance with the monthly vesting schedule that originally was applicable to such option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.59 · Expires 2026-12-21	Direct	Reported balance After 2018-11-27 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2018-11-27 · Disposition to issuer · Disposed 18,118 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested option to purchase Shares that was unexpired, unexercised and outstanding was converted into and substituted for the right to receive an amount equal to the product of (x) the number of unvested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option. This consideration will be paid monthly in accordance with the monthly vesting schedule that originally was applicable to such option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.59 · Expires 2027-11-30	Direct	Reported balance After 2018-11-27 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2018-11-27 · Disposition to issuer · Disposed 29,896 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested option to purchase Shares that was unexpired, unexercised and outstanding was converted into and substituted for the right to receive an amount equal to the product of (x) the number of unvested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option. This consideration will be paid monthly in accordance with the monthly vesting schedule that originally was applicable to such option.
Restricted Stock Units (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2018-11-27 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2018-11-27 · Disposition to issuer · Disposed 8,437 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested RSU outstanding that had not yet been settled was converted into and substituted for the right to receive an amount equal to the product of (x) the number of Shares issuable under such RSU multiplied by $12.50. This consideration will be paid annually in accordance with the annual vesting schedule that originally was applicable to such RSU. F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR").
Restricted Stock Units (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2018-11-27 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2018-11-27 · Disposition to issuer · Disposed 8,750 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested RSU outstanding that had not yet been settled was converted into and substituted for the right to receive an amount equal to the product of (x) the number of Shares issuable under such RSU multiplied by $12.50. This consideration will be paid annually in accordance with the annual vesting schedule that originally was applicable to such RSU. F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR").

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR").

F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.

F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested option to purchase Shares that was unexpired, unexercised and outstanding was converted into and substituted for the right to receive an amount equal to the product of (x) the number of unvested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option. This consideration will be paid monthly in accordance with the monthly vesting schedule that originally was applicable to such option.

F4: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested RSU outstanding that had not yet been settled was converted into and substituted for the right to receive an amount equal to the product of (x) the number of Shares issuable under such RSU multiplied by $12.50. This consideration will be paid annually in accordance with the annual vesting schedule that originally was applicable to such RSU.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 23, 2023 Filed Mar 27, 2023 19:56 UTC	CalciMedica, Inc. GRAY · Entity 7804	Disposition to issuerRestricted Stock Unit · Derivative	36,657	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-021300 · doc4.xml · derivative · entry 3 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,657 shares Expires not disclosed F1 · derivative.exercise_price: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Robert S. Breuil's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. F1 · price: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Robert S. Breuil's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. F1 · derivative.exercise_date: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Robert S. Breuil's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. F1 · derivative.expiration_date: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Robert S. Breuil's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. Read SEC document
March 23, 2023 Filed Mar 27, 2023 19:56 UTC	CalciMedica, Inc. GRAY · Entity 7804	Tax withholdingCommon Stock	12,677	$5.50	$69,723.50	Disclosure SEC source: 0001209191-23-021300 · doc4.xml · nonDerivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,326 Read SEC document
March 23, 2023 Filed Mar 27, 2023 19:56 UTC	CalciMedica, Inc. GRAY · Entity 7804	Disposition to issuerCommon Stock	36,657	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-021300 · doc4.xml · nonDerivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,003 F1 · price: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Robert S. Breuil's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. Read SEC document
March 14, 2023 Filed Mar 15, 2023 16:15 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionRestricted Stock Units · Derivative	5,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-018885 · doc4.xml · derivative · entry 3 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on September 4, 2021, and 1/12 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on September 4, 2024, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document
March 14, 2023 Filed Mar 15, 2023 16:15 UTC	CalciMedica, Inc. GRAY · Entity 7804	Tax withholdingCommon Stock	1,730	$0.58	$1,003.40	Disclosure SEC source: 0001209191-23-018885 · doc4.xml · nonDerivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,119 Read SEC document
March 14, 2023 Filed Mar 15, 2023 16:15 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionCommon Stock	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-018885 · doc4.xml · nonDerivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
March 03, 2023 Filed Mar 6, 2023 18:59 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionRestricted Stock Unit · Derivative	28,125	$0.00	$0.00	Disclosure SEC source: 0001209191-23-016509 · doc4.xml · derivative · entry 5 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,750 Underlying: Common Stock · 28,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs shall vested as to 6.25% of the total shares on November 16, 2022, and 6.25% of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on August 16, 2026, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document
March 03, 2023 Filed Mar 6, 2023 18:59 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionRestricted Stock Unit · Derivative	83,155	$0.00	$0.00	Disclosure SEC source: 0001209191-23-016509 · doc4.xml · derivative · entry 4 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,155 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs shall vested as to 100% of the total RSUs on February 28, 2023 and settled on March 3, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document
March 03, 2023 Filed Mar 6, 2023 18:59 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionRestricted Stock Units · Derivative	9,937	$0.00	$0.00	Disclosure SEC source: 0001209191-23-016509 · doc4.xml · derivative · entry 3 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,438 Underlying: Common Stock · 9,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document
March 03, 2023 Filed Mar 6, 2023 18:59 UTC	CalciMedica, Inc. GRAY · Entity 7804	Tax withholdingCommon Stock	49,434	$0.57	$28,177.38	Disclosure SEC source: 0001209191-23-016509 · doc4.xml · nonDerivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,849 Read SEC document
March 03, 2023 Filed Mar 6, 2023 18:59 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionCommon Stock	121,217	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-016509 · doc4.xml · nonDerivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
December 12, 2022 Filed Dec 14, 2022 16:07 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionRestricted Stock Units · Derivative	5,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-061177 · doc4.xml · derivative · entry 3 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on September 4, 2021, and 1/12 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on September 4, 2024, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document
December 12, 2022 Filed Dec 14, 2022 16:07 UTC	CalciMedica, Inc. GRAY · Entity 7804	Tax withholdingCommon Stock	1,729	$0.58	$1,002.82	Disclosure SEC source: 0001209191-22-061177 · doc4.xml · nonDerivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,066 Read SEC document
December 12, 2022 Filed Dec 14, 2022 16:07 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionCommon Stock	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-061177 · doc4.xml · nonDerivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
December 01, 2022 Filed Dec 1, 2022 16:50 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionRestricted Stock Units · Derivative	9,938	$0.00	$0.00	Disclosure SEC source: 0001209191-22-059207 · doc4.xml · derivative · entry 3 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,375 Underlying: Common Stock · 9,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document
December 01, 2022 Filed Dec 1, 2022 16:50 UTC	CalciMedica, Inc. GRAY · Entity 7804	Tax withholdingCommon Stock	3,437	$0.63	$2,165.31	Disclosure SEC source: 0001209191-22-059207 · doc4.xml · nonDerivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,795 Read SEC document
December 01, 2022 Filed Dec 1, 2022 16:50 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionCommon Stock	9,938	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-059207 · doc4.xml · nonDerivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
November 24, 2022 Filed Nov 29, 2022 16:38 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionRestricted Stock Units · Derivative	28,125	$0.00	$0.00	Disclosure SEC source: 0001209191-22-058951 · doc4.xml · derivative · entry 3 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,875 Underlying: Common Stock · 28,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs shall vested as to 6.25% of the total shares on November 16, 2022, and 6.25% of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on August 16, 2026, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document
November 24, 2022 Filed Nov 29, 2022 16:38 UTC	CalciMedica, Inc. GRAY · Entity 7804	Tax withholdingCommon Stock	9,726	$0.67	$6,516.42	Disclosure SEC source: 0001209191-22-058951 · doc4.xml · nonDerivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,294 Read SEC document
November 24, 2022 Filed Nov 29, 2022 16:38 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionCommon Stock	28,125	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-058951 · doc4.xml · nonDerivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
September 23, 2022 Filed Sep 26, 2022 16:17 UTC	CalciMedica, Inc. GRAY · Entity 7804	Tax withholdingCommon Stock	1,684	$0.97	$1,626.91	Disclosure SEC source: 0001209191-22-051242 · doc4.xml · nonDerivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,895 Read SEC document
September 04, 2022 Filed Sep 26, 2022 16:17 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionRestricted Stock Units · Derivative	5,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-051242 · doc4.xml · derivative · entry 3 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/12 of the total shares on September 4, 2022, but were not settled and issued until September 23, 2022. 1/12 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on September 4, 2024, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document
September 04, 2022 Filed Sep 26, 2022 16:17 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionCommon Stock	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-051242 · doc4.xml · nonDerivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
August 24, 2022 Filed Aug 26, 2022 16:49 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantRestricted Stock Units · Derivative	450,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-22-047724 · doc4.xml · derivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs shall vest as to 6.25% of the total shares on November 16, 2022, and 6.25% of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on August 16, 2026, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document
August 19, 2022 Filed Aug 23, 2022 17:17 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionRestricted Stock Units · Derivative	9,937	$0.00	$0.00	Disclosure SEC source: 0001209191-22-047234 · doc4.xml · derivative · entry 3 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,313 Underlying: Common Stock · 9,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document
August 19, 2022 Filed Aug 23, 2022 17:17 UTC	CalciMedica, Inc. GRAY · Entity 7804	Tax withholdingCommon Stock	3,347	$0.97	$3,246.59	Disclosure SEC source: 0001209191-22-047234 · doc4.xml · nonDerivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,579 Read SEC document
August 19, 2022 Filed Aug 23, 2022 17:17 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionCommon Stock	9,937	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-047234 · doc4.xml · nonDerivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
June 09, 2022 Filed Jun 13, 2022 17:06 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionRestricted Stock Units · Derivative	5,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-036381 · doc4.xml · derivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on September 4, 2021 but did not settle until September 22, 2021. 1/12 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on September 4, 2024, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document
June 09, 2022 Filed Jun 13, 2022 17:06 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionCommon Stock	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-036381 · doc4.xml · nonDerivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
May 19, 2022 Filed May 23, 2022 16:48 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionRestricted Stock Units · Derivative	39,750	$0.00	$0.00	Disclosure SEC source: 0001209191-22-031353 · doc4.xml · derivative · entry 3 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,250 Underlying: Common Stock · 39,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document
May 19, 2022 Filed May 23, 2022 16:48 UTC	CalciMedica, Inc. GRAY · Entity 7804	Tax withholdingCommon Stock	16,290	$0.90	$14,678.92	Disclosure SEC source: 0001209191-22-031353 · doc4.xml · nonDerivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,989 Read SEC document
May 19, 2022 Filed May 23, 2022 16:48 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionCommon Stock	39,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-031353 · doc4.xml · nonDerivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
March 31, 2022 Filed Apr 4, 2022 17:41 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionRestricted Stock Units · Derivative	5,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-022591 · doc4.xml · derivative · entry 3 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vested as to 1/12 of the total shares on March 4, 2022, but were not settled and issued until March 31, 2022. 1/12 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on September 4, 2024, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F4 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document
March 31, 2022 Filed Apr 4, 2022 17:41 UTC	CalciMedica, Inc. GRAY · Entity 7804	SaleCommon Stock	2,188	$1.25	$2,735.00	Disclosure SEC source: 0001209191-22-022591 · doc4.xml · nonDerivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,529 F2 · kind: Represents the aggregate number of shares sold by the Reporting Person to cover taxes and fees due upon the release and settlement of the Restricted Stock Units ("RSUs"). The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. Read SEC document
March 31, 2022 Filed Apr 4, 2022 17:41 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionCommon Stock	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-022591 · doc4.xml · nonDerivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
February 28, 2022 Filed Mar 2, 2022 18:55 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantRestricted Stock Unit · Derivative	83,155	$0.00	$0.00	Disclosure SEC source: 0001209191-22-015048 · doc4.xml · derivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,155 Underlying: Common Stock · 83,155 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs shall vests as to 100% of the total RSUs on February 28, 2023, subject to the Reporting Person's provision of service to the Issuer on the vesting date. F3 · derivative.expiration_date: The RSUs shall vests as to 100% of the total RSUs on February 28, 2023, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document
February 28, 2022 Filed Mar 2, 2022 18:55 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantEmployee Stock Option (Right to Buy) · Derivative	63,845	$0.00 Strike: $1.33	$0.00	Disclosure SEC source: 0001209191-22-015048 · doc4.xml · derivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,845 Underlying: Common Stock · 63,845 shares Expires 2032-02-27 F1 · derivative.exercise_date: The stock option vests as to 100% of the total shares on February 28, 2023, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document
December 04, 2021 Filed Dec 7, 2021 18:52 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionRestricted Stock Units · Derivative	5,000	$0.00	$0.00	Disclosure SEC source: 0001209191-21-068421 · doc4.xml · derivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on September 4, 2021 but did not settle until September 22, 2021. 1/12 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on September 4, 2024, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document
December 04, 2021 Filed Dec 7, 2021 18:52 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionCommon Stock	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-068421 · doc4.xml · nonDerivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
September 22, 2021 Filed Sep 24, 2021 19:16 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionRestricted Stock Units · Derivative	20,000	$0.00	$0.00	Disclosure SEC source: 0001209191-21-057712 · doc4.xml · derivative · entry 3 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on September 4, 2021, but were not settled and issued until September 22, 2021. 1/12 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on September 4, 2024, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F5 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document
September 22, 2021 Filed Sep 24, 2021 19:16 UTC	CalciMedica, Inc. GRAY · Entity 7804	SaleCommon Stock	7,283	$3.55	$25,853.92	Disclosure SEC source: 0001209191-21-057712 · doc4.xml · nonDerivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,717 F2 · kind: Represents the aggregate number of shares sold by the Reporting Person to cover taxes and fees due upon the release and settlement of the Restricted Stock Units ("RSUs"). The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.47 to $3.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 22, 2021 Filed Sep 24, 2021 19:16 UTC	CalciMedica, Inc. GRAY · Entity 7804	Exercise / conversionCommon Stock	20,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-057712 · doc4.xml · nonDerivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
May 19, 2021 Filed May 21, 2021 16:21 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantRestricted Stock Units · Derivative	159,000	$0.00	$0.00	Disclosure SEC source: 0001209191-21-034906 · doc4.xml · derivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,000 Underlying: Common Stock · 159,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs shall vest as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F4 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document
May 19, 2021 Filed May 21, 2021 16:21 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantEmployee Stock Option (Right to Buy) · Derivative	232,000	$0.00 Strike: $3.73	$0.00	Disclosure SEC source: 0001209191-21-034906 · doc4.xml · derivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,000 Underlying: Common Stock · 232,000 shares Expires 2031-05-18 F1 · derivative.exercise_date: The stock option vests as to 1/4 of the total shares on May 19, 2022 and then 1/48 of the total shares monthly until the option is fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
December 08, 2020 Filed Dec 10, 2020 17:08 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantEmployee Stock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $23.66	$0.00	Disclosure SEC source: 0001209191-20-062751 · doc4.xml · derivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-12-07 F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares on January 8, 2021 and each month thereafter until option is fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
September 24, 2020 Filed Sep 28, 2020 17:38 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantRestricted Stock Units · Derivative	80,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-20-052240 · doc4.xml · derivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs shall vest as to 1/4 of the total shares on September 4, 2021, and 1/12 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on September 4, 2024, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document
November 27, 2018 Filed Nov 28, 2018 19:49 UTC	Corium International, Inc. CORI · Entity 162158	Disposition to issuerRestricted Stock Units (RSU) · Derivative	8,750	$12.50	$109,375.00	Disclosure SEC source: 0001567619-18-007063 · doc1.xml · derivative · entry 19 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested RSU outstanding that had not yet been settled was converted into and substituted for the right to receive an amount equal to the product of (x) the number of Shares issuable under such RSU multiplied by $12.50. This consideration will be paid annually in accordance with the annual vesting schedule that originally was applicable to such RSU. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested RSU outstanding that had not yet been settled was converted into and substituted for the right to receive an amount equal to the product of (x) the number of Shares issuable under such RSU multiplied by $12.50. This consideration will be paid annually in accordance with the annual vesting schedule that originally was applicable to such RSU. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested RSU outstanding that had not yet been settled was converted into and substituted for the right to receive an amount equal to the product of (x) the number of Shares issuable under such RSU multiplied by $12.50. This consideration will be paid annually in accordance with the annual vesting schedule that originally was applicable to such RSU. Read SEC document
November 27, 2018 Filed Nov 28, 2018 19:49 UTC	Corium International, Inc. CORI · Entity 162158	Disposition to issuerRestricted Stock Units (RSU) · Derivative	8,437	$12.50	$105,462.50	Disclosure SEC source: 0001567619-18-007063 · doc1.xml · derivative · entry 18 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,437 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested RSU outstanding that had not yet been settled was converted into and substituted for the right to receive an amount equal to the product of (x) the number of Shares issuable under such RSU multiplied by $12.50. This consideration will be paid annually in accordance with the annual vesting schedule that originally was applicable to such RSU. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested RSU outstanding that had not yet been settled was converted into and substituted for the right to receive an amount equal to the product of (x) the number of Shares issuable under such RSU multiplied by $12.50. This consideration will be paid annually in accordance with the annual vesting schedule that originally was applicable to such RSU. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested RSU outstanding that had not yet been settled was converted into and substituted for the right to receive an amount equal to the product of (x) the number of Shares issuable under such RSU multiplied by $12.50. This consideration will be paid annually in accordance with the annual vesting schedule that originally was applicable to such RSU. Read SEC document
November 27, 2018 Filed Nov 28, 2018 19:49 UTC	Corium International, Inc. CORI · Entity 162158	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	29,896	$12.50 Strike: $11.59	$373,700.00	Disclosure SEC source: 0001567619-18-007063 · doc1.xml · derivative · entry 17 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,896 shares Expires 2027-11-30 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested option to purchase Shares that was unexpired, unexercised and outstanding was converted into and substituted for the right to receive an amount equal to the product of (x) the number of unvested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option. This consideration will be paid monthly in accordance with the monthly vesting schedule that originally was applicable to such option. Read SEC document
November 27, 2018 Filed Nov 28, 2018 19:49 UTC	Corium International, Inc. CORI · Entity 162158	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	18,118	$12.50 Strike: $4.59	$226,475.00	Disclosure SEC source: 0001567619-18-007063 · doc1.xml · derivative · entry 16 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,118 shares Expires 2026-12-21 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each unvested option to purchase Shares that was unexpired, unexercised and outstanding was converted into and substituted for the right to receive an amount equal to the product of (x) the number of unvested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option. This consideration will be paid monthly in accordance with the monthly vesting schedule that originally was applicable to such option. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.